List view / Grid view

Ann E Cleves (VP of Application Science for Optibrium’s BioPharmics Division)

 

article

Obstacles and innovations of macrocyclic drug development

16 January 2025 | By ,

Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.